Celcuity Inc.

Stage 4 · Declining · week 13

As of Oct 22, 2026, Celcuity is in Stage 4, the downtrend phase, now in week 13 (since Jul 29, 2026). It closed at $65.57, 54.8% below its 52-week high and below its 200-day average, which is falling.

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. More about the company

$65.57

+6.51% today

$3.2B · Mid cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CELC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 26w

S4 35w

S2 47w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 12w → S1 2w → S2 26w → S3 8w → S2 8w → S3 1w → S4 35w → S1 8w → S2 47w → S3 6w → S4 12w current

Total tracked: 166 weeks across 11 stage runs.

CELC among Biotechnology189th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…189	CELCCelcuity Inc.	Stage 4 · wk 13	54	−18.0%

vs 52W High

-54.8%

$56.58 lo$144.98 hi

54.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 13

1w13w26w

Week 13, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-35.6%

200 DMA: $101.82 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.55x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-18.0%

-20.6%

-42.3%

YTD

-34.8%

+0.1%

Scan Membership

Breakout Watch

Latest: 2024-07-24

7 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 13 · Vol 1.55x

2026-10-21S4

Wk 12 · Vol 1.02x

2026-10-20S4

Wk 12 · Vol 1.99x

2026-10-19S4

Wk 12 · Vol 2.31x

2026-10-16S4

Wk 12 · Vol 4.01x

2026-10-15S4

Wk 12 · Vol 2.01x

2026-10-14S4

Wk 11 · Vol 2.39x

2026-10-13S4

Wk 11 · Vol 1.50x

2026-10-12S4

Wk 11 · Vol 1.06x

2026-10-09S4

Wk 11 · Vol 1.29x

2026-10-08S4

Wk 11 · Vol 2.67x

2026-10-07S4

Wk 10 · Vol 3.34x

Moving averages & range

50 DMA

$80.50

200 DMA

$101.82

52W High

$144.98

52W Low

$56.58

5D Low

$56.58

Resistance levels (recent highs)

20d High

$79.64

60d High

$96.43

120d High

$144.98

250d High

$144.98

Next resistance

+21.5%

to 20d High

ROE

-1433.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B -251.2

Celcuity: quick answers

What stage is Celcuity in?

As of Oct 22, 2026, Celcuity (CELC) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 29, 2026 and is in week 13. What the four stages mean

Is Celcuity in an uptrend?

No. Celcuity is in a Stage 4 downtrend. It trades 35.6% below its 200-day average, which is falling.

How far is Celcuity from its 52-week high?

Celcuity closed at $65.57 on Oct 22, 2026, 54.8% below its 52-week high of $144.98. Its 52-week low is $56.58.

How has Celcuity performed over the past year?

As of Oct 22, 2026, Celcuity is up 0.1% over the past year and down 34.8% so far in 2026.

Which sector and industry is Celcuity in?

Celcuity is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.